Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Champlin

Showing results (421-430 of 768) with videos related to

Pageof 77
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 21, 2008
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDSBorje S Andersson, Marcos de Lima, Peter F Thall, et al.
Haematologica|July 13, 2019
Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantationSamer A Srour, Amanda Olson, Stefan O Ciurea, et al.
Bone Marrow Transplantation|July 27, 2004
Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease responseP Anderlini, S A Acholonu, G-J Okoroji, et al.
Plos One|June 7, 2013
Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cellsHarjeet Singh, Matthew J Figliola, Margaret J Dawson, et al.
Medicine|November 16, 2007
Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005Amar Safdar, Gilhen H Rodriguez, Marcos J De Lima, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 26, 2014
Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancyMary Eapen, Brent R Logan, Fredrick R Appelbaum, et al.
Cancer|April 28, 2006
Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 yearsEmer O Hanrahan, Kristine Broglio, Deborah Frye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Impact of high-dose chemotherapy on peripheral T-cell lymphomasJ Rodriguez, M Munsell, S Yazji, et al.
British Journal of Haematology|May 10, 2017
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term resultsSamer A Srour, Shaoying Li, Uday R Popat, et al.
Cancer|February 27, 2020
Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomesFevzi F Yalniz, Keyur P Patel, Qaiser Bashir, et al.
Pageof 77

Showing results (421-430 of 768) with videos related to

Sort By:
Pageof 77
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 21, 2008
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDSBorje S Andersson, Marcos de Lima, Peter F Thall, et al.
Haematologica|July 13, 2019
Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantationSamer A Srour, Amanda Olson, Stefan O Ciurea, et al.
Bone Marrow Transplantation|July 27, 2004
Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease responseP Anderlini, S A Acholonu, G-J Okoroji, et al.
Plos One|June 7, 2013
Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cellsHarjeet Singh, Matthew J Figliola, Margaret J Dawson, et al.
Medicine|November 16, 2007
Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005Amar Safdar, Gilhen H Rodriguez, Marcos J De Lima, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 26, 2014
Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancyMary Eapen, Brent R Logan, Fredrick R Appelbaum, et al.
Cancer|April 28, 2006
Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 yearsEmer O Hanrahan, Kristine Broglio, Deborah Frye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Impact of high-dose chemotherapy on peripheral T-cell lymphomasJ Rodriguez, M Munsell, S Yazji, et al.
British Journal of Haematology|May 10, 2017
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term resultsSamer A Srour, Shaoying Li, Uday R Popat, et al.
Cancer|February 27, 2020
Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomesFevzi F Yalniz, Keyur P Patel, Qaiser Bashir, et al.
Pageof 77